Sanofi SA (SNY)
49.11
-0.35
(-0.71%)
USD |
NASDAQ |
May 03, 13:18
Sanofi Enterprise Value: 132.01B for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 132.01B |
| May 01, 2024 | 133.44B |
| April 30, 2024 | 131.44B |
| April 29, 2024 | 131.09B |
| April 26, 2024 | 131.19B |
| April 25, 2024 | 131.76B |
| April 24, 2024 | 124.90B |
| April 23, 2024 | 127.59B |
| April 22, 2024 | 126.25B |
| April 19, 2024 | 124.12B |
| April 18, 2024 | 121.85B |
| April 17, 2024 | 123.65B |
| April 16, 2024 | 122.88B |
| April 15, 2024 | 123.98B |
| April 12, 2024 | 123.20B |
| April 11, 2024 | 124.87B |
| April 10, 2024 | 126.20B |
| April 09, 2024 | 127.20B |
| April 08, 2024 | 126.25B |
| April 05, 2024 | 126.50B |
| April 04, 2024 | 127.87B |
| April 03, 2024 | 128.27B |
| April 02, 2024 | 127.62B |
| April 01, 2024 | 129.09B |
| March 31, 2024 | 129.87B |
| Date | Value |
|---|---|
| March 28, 2024 | 129.87B |
| March 27, 2024 | 132.21B |
| March 26, 2024 | 132.74B |
| March 25, 2024 | 131.96B |
| March 22, 2024 | 128.54B |
| March 21, 2024 | 127.69B |
| March 20, 2024 | 128.94B |
| March 19, 2024 | 127.07B |
| March 18, 2024 | 127.94B |
| March 15, 2024 | 129.09B |
| March 14, 2024 | 128.59B |
| March 13, 2024 | 128.97B |
| March 12, 2024 | 129.52B |
| March 11, 2024 | 129.24B |
| March 08, 2024 | 128.99B |
| March 07, 2024 | 128.52B |
| March 06, 2024 | 127.57B |
| March 05, 2024 | 127.12B |
| March 04, 2024 | 126.25B |
| March 01, 2024 | 126.60B |
| February 29, 2024 | 127.99B |
| February 28, 2024 | 128.40B |
| February 27, 2024 | 128.93B |
| February 26, 2024 | 128.90B |
| February 23, 2024 | 130.32B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
106.37B
Minimum
Sep 27 2022
154.26B
Maximum
Apr 11 2022
134.87B
Average
135.87B
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 260.36B |
| GSK PLC | 104.89B |
| Novo Nordisk A/S | 555.81B |
| Regeneron Pharmaceuticals Inc | 94.05B |
| Biophytis SA | 2.480M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.231B |
| Revenue (Quarterly) | 12.08B |
| Total Expenses (Quarterly) | 9.653B |
| EPS Diluted (Quarterly) | 0.4942 |
| Gross Profit Margin (Quarterly) | 69.07% |
| Profit Margin (Quarterly) | 10.19% |
| Earnings Yield | 4.03% |
| Operating Earnings Yield | 8.66% |
| Normalized Earnings Yield | 6.025 |